Article

Cancer survivors sought for online study

Author(s):

Researchers at Stanford University School of Medicine and The Cancer Research Center of Hawaii are recruiting participants for a study that hopes to improve the lives of cancer survivors."Cancer: Thriving & Surviving" is a six-week, Internet-based workshop to help cancer survivors adjust to life after cancer. Many survivors have unique issues after completing treatment; they may struggle with physical changes, late effects of treatment, emotional concerns, and/or the stress of recurrence.Researchers hope this interactive workshop will help survivors through some of these issues. Each workshop will bring together about 25 survivors and will be facilitated by two trained moderators, one of whom is a cancer survivor. Participants will also have access to an online learning center and discussion boards, and will be asked to log in at their convenience two or three times for a total of about two hours a week during the six-week workshop. This study will assess the effectiveness of this program. The workshop is based on Stanford's "Healthier Living with Chronic Conditions Self-Management Program," which showed in a similar study that participants who developed confidence in managing their own health required fewer medical interventions and were overall healthier. Researchers are looking for about 400 survivors who have completed treatment to participate in this study. For more information and requirements, go to cancersurvivors.stanford.edu or email cancersurvivors@standford.edu.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content